Biomarkers in Inflammatory Bowel Diseases: Predicting the Indication and the Effect of Biologics.

G Tarapatzi, E Filidou… - … of Gastrointestinal & …, 2022 - search.ebscohost.com
Crohn's disease and ulcerative colitis, the two most common inflammatory bowel diseases
(IBD), are characterized by chronic relapsing inflammation. Although recent progress …
被引用次数：3 相关文章

Biomarkers in inflammatory bowel diseases: predicting the indication and the effect of biologics.

G Tarapatzi, E Filidou, L Kandilogiannakis, S Vradelis… - 2022 - cabidigitallibrary.org
Crohn's disease and ulcerative colitis, the two most common inflammatory bowel diseases
(IBD), are characterized by chronic relapsing inflammation. Although recent progress …

Biomarkers in Inflammatory Bowel Diseases: Predicting the Indication and the Effect of Biologics.

G Tarapatzi, E Filidou, L Kandilogiannakis… - … and Liver Diseases …, 2022 - europepmc.org
Crohn's disease and ulcerative colitis, the two most common inflammatory bowel diseases
(IBD), are characterized by chronic relapsing inflammation. Although recent progress …

Biomarkers in Inflammatory Bowel Diseases: Predicting the Indication and the Effect of Biologics

G Tarapatzi, E Filidou, L Kandilogiannakis… - … of Gastrointestinal and …, 2022 - elibrary.ru
Crohn's disease and ulcerative colitis, the two most common inflammatory bowel diseases
(IBD), are characterized by chronic relapsing inflammation. Although recent progress …

Biomarkers in Inflammatory Bowel Diseases: Predicting the Indication and the Effect of Biologics

G Tarapatzi, E Filidou… - … and liver diseases …, 2022 - pubmed.ncbi.nlm.nih.gov
Crohn's disease and ulcerative colitis, the two most common inflammatory bowel diseases
(IBD), are characterized by chronic relapsing inflammation. Although recent progress …